Kristofer Dosh, MD
Cardiovascular Disease · Green Bay, WINPI 1790999092
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 40.1% of the total. 2025 is the largest year on record at $2,947, 3.7 times the $799 reported in 2019.
Across 143 payments — averaging $61.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Edwards Lifesciences$2K
- Abbott$2K
- Medtronic$538
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$227
- AstraZeneca$215
- plus $1K from 12 others
Across 5 payments — averaging $1391.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medical Device Business Services, Inc.$7K
What the payments were for
- Travel & lodging$4,16547%
- Food & beverage$4,59652%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 27 | $3,541 |
| Edwards Lifesciences | 10 | $1,595 |
| Abbott | 15 | $1,568 |
| Medtronic(2 entities) | 14 | $538 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $227 |
| AstraZeneca | 11 | $215 |
| Novartis | 19 | $207 |
| Philips North America LLC | 3 | $168 |
| Abiomed | 2 | $163 |
| Cardiovascular Systems Inc. | 6 | $155 |
| W. L. Gore & Associates, Inc. | 2 | $128 |
| Surmodics, Inc. | 5 | $80 |
| Amgen | 4 | $76 |
| Johnson & Johnson | 4 | $57 |
| Stryker | 1 | $53 |
| Pfizer | 2 | $28 |
| Shockwave Medical, Inc | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,835 in reported general payments places this provider in the 85th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $109,727 |
| XareltoRivaroxaban | 22 | $24,710 |
| EntrestoSacubitril/Valsartan | 26 | $19,229 |
| Repatha SureclickEvolocumab | 22 | $17,815 |
| Amiodarone Hcl | 24 | $1,339 |
| Metoprolol Succinate | 89 | $1,287 |
| Atorvastatin Calcium | 63 | $1,097 |
| ClopidogrelClopidogrel Bisulfate | 69 | $984 |
| Rosuvastatin Calcium | 59 | $777 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 79 | $774 |
| Amlodipine Besylate | 77 | $604 |
| Losartan Potassium | 50 | $557 |
| Carvedilol | 51 | $552 |
| Ezetimibe | 27 | $542 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $109,727107 claims |
| Johnson & JohnsonXarelto | $57 | $24,71022 claims |
| NovartisEntresto | $207 | $19,22926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Green Bay
- Arbind ChaudharyGreen Bay$42K
- Abdul SafadiGreen Bay$28K
- Anas SarhanGreen Bay$25K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.